| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fosaprepitant (Ivemend®) |
| Formulation | 150 mg powder for solution for infusion |
| Reference number | 151 |
| Indication | Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy; prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy; given as part of a combination therapy |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 11/04/2008 |